The California Stem Cell Report

Home
sustainability
cirm future
CIRM's $3.9 Billion Priority …
A CIRM Primer -- A to Z
Leaderboard
About

sustainability

Sustainability Study to Begin: 'Existential Reality' Confronts $12 Billion California Stem Cell/Gene Therapy Agency
SOUTH SAN FRANCISCO -- The chairman of California’s $12 billion stem cell and gene therapy agency announced a new effort yesterday to devise a plan to…
 • 
David Jensen
The California Stem Cell Program's Paucity of Critics
Despite its billions, CIRM is little known to the public and even potential opponents
 • 
David Jensen
Six Month Pause on Research Applications at California's Stem Cell and Gene Therapy Program
Multibillion-dollar enterprise needs time to work through its sweeping, new priorities
 • 
David Jensen
Want to Help Plan the Financial Future of a Multibillion-Dollar, Biomedical, California Research Enterprise?
The job involves 'CIRM's lifespan' along with audits and accounting.
 • 
David Jensen
Text from UCLA Researcher Donald Kohn on his Bubble Baby Clinical Trial
Status report and treatment of five-year-old Jakob included
 • 
David Jensen
Dr. Moustache and the Bubble Baby Disease: A CIRM Success Story
More than 50 patients treated successfully, but a commercialization caveat
 • 
David Jensen
Trail Guide to $3.9 Billion in Looming Changes at California's Stem Cell and Gene Therapy Program
Who wins, who loses? The priority review is laying the groundwork for decisions about dollars.
 • 
David Jensen
Looking for Work? Want to Help Give Away Billions of Dollars?
The California stem cell agency is looking for six good helpers
 • 
David Jensen
Less Than Probing: Financial Examination of $12 Billion Stem Cell Research Program Skims Quickly Over the Numbers
Not discussed are CIRM's sustainability and its self-identified risks; session held behind closed electronic doors
 • 
David Jensen
Dysfunction, Bifurcated Management and $12 Billion: A Call for Reevalution of CIRM
Longtime member of CIRM financial oversight panel resigns, citing 'surpassed tolerance limits'
 • 
David Jensen
2
From CEO to Financial: Risks in California's Multibillion-Dollar Stem Cell/Genetic Research Program
CIRM identifies uncertainties involved in its efforts
 • 
David Jensen
CIRM's Priorities and Spending: From the Impact of Past Research Investments to Prevalance of Diseases in California
State funding for gene and stem cell therapies to involve "patient reach" and likelihood of regulatory approval
 • 
David Jensen
© 2024 David Jensen
Privacy ∙ Terms ∙ Collection notice
Start WritingGet the app
Substack is the home for great culture